TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05737940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3427
Description: The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.
Study: NCT05260060

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual: Control
Description: Treatment usually delivered in service that may include but is not limited to cognitive behaviour therapy, exposure, eye movement desensitisation and reprocessing , behaviour therapy, family therapy.
Study: NCT06367296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged resistance exercise training
Description: Training with resistance exercises for upper and lower limbs will be carried out 3 times a week (Monday, Wednesday and Friday) for 12 weeks for all participants. The training will follow the guidelines of the American College of Sports Medicine (American College of Sports Medicine Position Stand. Progression Models in Resistance Training for Healthy Adults, 2009) and will consist of a 5-minute cardiovascular warm-up on a cycle ergometer, followed by weight training. Resistance training will be carried out with exercise machines: 5 sets of leg press, leg extension and leg flexion for lower limbs and 3 sets of chest press and triceps extension for upper limbs. Subsequently, the participants will perform global flexibility exercises for 5 minutes to return to calm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolonged resistance exercise training
Description: Training with resistance exercises for upper and lower limbs will be carried out 3 times a week (Monday, Wednesday and Friday) for 12 weeks for all participants. The training will follow the guidelines of the American College of Sports Medicine (American College of Sports Medicine Position Stand. Progression Models in Resistance Training for Healthy Adults, 2009) and will consist of a 5-minute cardiovascular warm-up on a cycle ergometer, followed by weight training. Resistance training will be carried out with exercise machines: 5 sets of leg press, leg extension and leg flexion for lower limbs and 3 sets of chest press and triceps extension for upper limbs. Subsequently, the participants will perform global flexibility exercises for 5 minutes to return to calm.
Study: NCT06393738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-393
Description: Oral dose of ARV-393 at a specified dose schedule will be taken in 28-day cycles
Study: NCT05859100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ≥ 2 eggs in addition to usual diet for 8 weeks
Description: Participants are expected to consume≥ 2 eggs per day in addition to usual diet for 8 weeks in early intervention arm, beginning immediately post-treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: ≥ 2 eggs in addition to usual diet for 4 weeks
Description: Participants are expected to continue intake of regular diet beginning immediately at post-treatment recovery for a duration of 4 weeks, then crossover to nutritional intervention arm from weeks 5 to 8 of post-treatment recovery for a duration of 4 weeks.
Study: NCT06133972

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo s.c. monthly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Ianalumab s.c. monthly Ianalumab s.c. quarterly
Study: NCT05260060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy (Group-MCT): Experimental
Description: Group metacognitive therapy (Group-MCT) focuses on developing adaptive control of worry, repetitive negative thinking and attention and modifies beliefs that maintain unhelpful thinking patterns. Treatment is 6 to 8 weekly sessions delivered by two trained mental health professionals, guided by a treatment manual, lasting approximately 90 minutes each session.
Study: NCT06270186

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Type 1 myotonic dystrophy
Description: To compare classical neuropsychological test and on Good Diag NMD software in Type 1 myotonic dystrophy patients
Study: NCT04868890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Inhaled Ampion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled Placebo
Study: NCT05765240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid Topical Gels
Description: Hyaluronic acid is a linear polysaccharide found naturally in different organs and tissues such as the extracellular matrix of connective tissue, synovial fluid, embryonic mesenchyme, and skin. The periodontal ligament is a key element found in periodontal tissues such as the gingiva, alveolar bone, and cementum. It plays a regulatory role in the inflammatory response, impedes the penetration of viruses and bacteria into the tissue, and is involved in inflammation, granulation tissue formation, epithelial formation, and tissue remodeling. There are no reported drug interactions or contraindications for the use of hyaluronic acid.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser Biostimulation
Description: Laser therapy can amplify wound healing by increasing cell regeneration and modulating the immune response. In animal experiments with diode laser, it was observed that postoperative low-level laser application increased wound healing. Diode laser applied at frequencies of 20 mW and 670 nm and 200 mW and 820 nm accelerated clot organization and new vessel formation after tooth extraction.
Study: NCT05117320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI support
Description: Images were allocated to participants. In randomized allocation, one half of the images for each participant are viewed with AI support and the other half is viewed without AI support on the first trial day. On the second trial day the same images are viewed without versus with AI, respectively. This ensures that all images are read twice by the same participant both with and without AI support.
Study: NCT04604821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Milieu Teaching
Description: A behavioral language intervention that uses naturally occurring interactions to facilitate young children's language skills.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent Education
Description: Parents receive information on child developmental milestones.
Study: NCT05127473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 10 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 10 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mim8 B, 10 mg/mL
Description: All participants will receive a single dose of Mim8 subcutaneously (s.c- under the skin) and will stay in-house at the site until 3 days after dosing.
Study: NCT05139784

Intervention type: OTHER
Intervention: Biosampling
Description: Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.

Intervention type: OTHER
Intervention: Biosampling
Description: Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.

Intervention type: OTHER
Intervention: Biosampling
Description: Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.

Intervention type: OTHER
Intervention: Biosampling
Description: Collection of blood and stool specimens; and collection of lymph node specimens for the group undergoing surgical lymphadenectomy.
Study: NCT06133972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab
Description: Ianalumab s.c. monthly Ianalumab s.c. quarterly
Study: NCT06042569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05775406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-253
Description: KT-253 will be administered intravenously per the defined protocol frequency and dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KT-253
Description: KT-253 will be administered intravenously per the defined protocol frequency and dose level.
Study: NCT06142253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WATER+CT
Description: This is an 8-month long two phase intervention. The first phase consists of 6 months of thrice weekly pool-based exercise occurring at VA Palo Alto. After completion of the 6 month long pool based exercise, participants transition to ten sessions of cognitive training that will occur over 2 months at the VA Palo Alto.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: This condition involves receipt of educational materials about brain health and healthy lifestyles as well as regular contact with study staff.
Study: NCT04577859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ensoETM. Esophageal cooling during AF ablation
Description: Esophageal cooling during AF ablation: The ensoETM probe is inserted via the orogastric route when the patient is under general anesthesia. The device is set to cool during ablation of the posterior aspect of the left atrium, to protect against transmitted thermal energy and so reduce or prevent esophageal thermal injury.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal temperature monitoring probe
Description: An esophageal temperature monitoring probe is a typical monitoring device used in standard of care AF ablations. This allows any temperature rise in the esophagus to be detected during ablation. If the temperature reaches \>38 degrees then it is widely recognized that ablation should be halted until the temperatures fall back to below 38 degrees. It therefore has the ability to detect esophageal temperature rise only.
Study: NCT06378086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA® Redensity with new anesthetic agent
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w of new anesthetic agent in a physiologic buffer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA® Redensity with lidocaine
Description: A sterile, biodegradable, biocompatible, viscoelastic, clear, colorless, homogenized gel implant. It consists of cross-linked hyaluronic acid produced by fermentation of Streptococcus zooepidemicus, formulated to a concentration of 15 mg/g and 0.3% w/w lidocaine in a physiologic buffer.
Study: NCT04773522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered subcutaneously.
Study: NCT06314373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39775 Monotherapy
Description: HSK39775 will be administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK39775 Monotherapy
Description: HSK39775 will be administered orally once daily
Study: NCT05512000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback with massed trials
Description: The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.
Study: NCT06411769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50K4LIfe
Description: This intervention will consist of the Walking Challenge only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50K4LIfe
Description: This intervention will consist of the Walking Challenge only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50K4LIfe
Description: This intervention will consist of the Walking Challenge only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50K4LIfe
Description: This intervention will consist of the Walking Challenge only.
Study: NCT05512000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback with massed trials
Description: The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback with spaced trials
Description: The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback with spaced trials
Description: The participant receives feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No feedback with massed trials
Description: The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No feedback with massed trials
Description: The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for one word are provided before moving to the next word in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No feedback with spaced trials
Description: The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No feedback with spaced trials
Description: The participant does not receive feedback on their accuracy completing retrieval practice tasks. Exposures for each word are interspersed with one another (e.g., an exposure for word 1, then one for word 3, then one for word 2, etc.) in each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No teaching control
Description: The words in this set are not taught, only assessed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No teaching control
Description: The words in this set are not taught, only assessed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No teaching control
Description: The words in this set are not taught, only assessed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No teaching control
Description: The words in this set are not taught, only assessed.
Study: NCT06194929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib will be administered at 200 mg twice daily orally per arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib will be administered at 200 mg twice daily orally per arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib will be administered at 200 mg twice daily orally per arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Avutometinib will be administered at 3.2 mg twice a week orally per arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Avutometinib will be administered at 3.2 mg twice a week orally per arm description.
Study: NCT06411769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50K4LIfe
Description: This intervention will consist of the Walking Challenge only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50K4LIfe
Description: This intervention will consist of the Walking Challenge only.
Study: NCT06194929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Avutometinib will be administered at 3.2 mg twice a week orally per arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafinib administered orally per arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Encorafinib administered orally per arm description.
Study: NCT05920343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 MG
Description: The intervention in the experimental arm will be rivaroxaban, 10 mg PO once daily (prophylactic dosing) for 180 days after the start of systemic therapy or until one of the primary study outcomes occurs (VTE or major bleeding).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Identical to Rivaroxaban intervention except participants will receive a matched placebo instead of the study drug
Study: NCT06411769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50K4LIfe
Description: This intervention will consist of the Walking Challenge only.
Study: NCT06517888

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AAVAnc80-antiVEGF via Akouos Delivery Device
Description: AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AAVAnc80-antiVEGF via Akouos Delivery Device
Description: AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AAVAnc80-antiVEGF via Akouos Delivery Device
Description: AAVAnc80-antiVEGF is a sterile suspension intended to be administered via intracochlear administration as a single dose using the Akouos Delivery Device
Study: NCT04360018

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol beverage
Description: High-proof alcohol (e.g., Everclear) will be mixed with orange juice in an approximately 1:3 ratio and split evenly into two drinks. After splitting the orange juice into two cups, a small amount (approx. 6 ml) of high-proof alcohol will be floated on top of the beverage.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beverage
Description: The final drink will have the same volume of liquid as the alcohol beverage.
Study: NCT04733079

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleanweb electronic messaging ePro
Description: Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual follow-up
Description: Adaptation and follow-up of ULT according to referring physician's habits
Study: NCT06324695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HautKompass
Description: The HautKompass program is a structured self-guided online psychosocial intervention designed to reduce self-stigma in people with visible chronic skin diseases. It combines educational content and practical exercises based on cognitive-behavioral therapy (CBT), namely cognitive restructuring of negative automatic thoughts and cultivating self-compassionate thinking and behavior. The program consists of eight skin-generic modules (on average, 15-20 minutes per module, one module per week).
Study: NCT05158205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12-week yoga intervention in which 60-minute classes are completed at Texas State University 3 times per week
Study: NCT06411769

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 50K4LIfe
Description: This intervention will consist of the Walking Challenge only.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: In this intervention, participants will received notifications onto the Pathverse app
Study: NCT05158205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow, deep breathing
Description: 12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control breathing
Description: 12-week home-based intervention in which 5 weekly 20-minute breathing sessions are completed
Study: NCT06210555

Intervention type: PROCEDURE
Intervention: Renal transplantation
Description: Operative procedure - receipt of a kidney

Intervention type: PROCEDURE
Intervention: Living kidney donation
Description: Operative procedure - donation of a kidney
Study: NCT05353387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interviewing will be carried out in 3 different sessions, each to be conducted one week apart. 6 weeks after the last interview, first follow up would be conducted through phone communication and 6 weeks after the first follow up, a face-to-face interview would be conducted for the scales to be applied to the participants again.
Study: NCT04979429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Pain Self-management (PePS)
Description: 4 sessions of telephone CBT-based pain self-management.